I operate at the intersection of AI, human genetics, and commercial strategy. At Genomics, I help pharmaceutical and biotech organizations bring large-scale human genetics into earlier, more confident R&D decision-making—through a combination of advanced analytics, AI-enabled tooling, and strategic consulting support.

My work centers on partnering with senior R&D, statistical genetics, and strategy leaders to operationalize genetics across the pipeline: accelerating target discovery, strengthening validation, improving translational confidence, and identifying patient populations more likely to respond to therapy.

Over the past 20 years, I’ve:

•	Built, led, and mentored high-performing sales teams in AI and SaaS.
•	Managed global accounts and developed go-to-market strategies that drive adoption.
•	Closed multi-million-dollar enterprise engagements and partnerships across R&D industries 
•	Negotiated strategic agreements that expand revenue and accelerate growth.

I’m also the author of Mastering AI Sales: Essential Knowledge for B2B Professionals, a practical playbook that equips founders, consultants, and sales leaders with frameworks to win complex AI sales.
👆 Now available – click the link in my profile header to get your copy.

Specialties

•	AI-Enabled Human Genetics / Genomics Commercial Strategy
•	Building & Scaling Sales Teams
•	Enterprise AI Sales & Stakeholder Management
•	Go-to-Market Strategy (Consulting + Product Hybrid Models)
•	Strategic Partnerships & Revenue Expansion
•	Cross-Functional Leadership & Commercial Alignment

Let’s connect if you’re scaling AI solutions, leading enterprise transformations, or looking to accelerate sales impact in complex markets.

David Walker

Early JPM takeaways…

• Causal genetics is firmly front and center, increasingly used to de-risk target identification and validate programs earlier in development.
• Patient stratification is no longer optional. Leaders are entering the clinic with greater emphasis on clear responder hypotheses and stronger supporting evidence.
• AI is maturing quickly. Fewer proof-of-concept discussions, more concrete examples of measurable impact across R&D.
• Funding sentiment appears cautiously improved, particularly for companies with differentiated science and disciplined, evidence-led strategies.

The Genomics leadership team is here all week and we’d be happy to connect and compare notes.

#jpm2026 #Genomics

VP of Client Service | Leading Enterprise AI Partnerships | Team Builder | Author of Mastering AI Sales | MBA, MSc.

JPM was an outstanding experience. The energy, quality of conversations, and level of innovation throughout the week were exceptional.

We were delighted to host a Genomics reception, where we shared how Mystra, our AI enabled platform, enables teams to apply human genetics more effectively to R&D decision-making. The depth of engagement reinforced just how central genetics has become to smarter target selection and clinical decisions.

A few key takeaways stood out for me…

1. Platforms must change decisions
AI creates value only when it changes decisions e.g. which targets advance, which programs stop earlier, and which patients enter trials. The strongest platforms enable fewer, higher-confidence bets.

2. Data advantage ≠ more data
The ultimate advantage is signal, not scale. Rare disease cohorts, longitudinal datasets, and multi-omics data with clinical context enable better questions to be asked and reduce false confidence.

3. Causal genetics is becoming foundational
Human genetics is increasingly being used to improve probability of success, de-risk programs earlier, enable patient stratification, and support smarter trial design.

The next phase of R&D won’t be defined by who moves fastest, but by who makes the best decisions earliest, using well-curated data, causal evidence, and AI together.

#JPM26 #Genetics #TargetValidation #PatientStratification #DrugDevelopment

Great to see the Genomics team out in force at #FOG2026 
If you’re at FOG, make sure you stop by by Booth #77 to say hello and check out the Mystra D&D Quest, a fun, hands-on way to experience how we support drug target discovery and development through human genetics and multi-omics.   Plus Dirk Paul, Head of Development, talking about: “The Genome and Beyond: Advancing Drug Discovery and Development” Today 12:00–12:30 | Multi-Omics Stage
Have a great show, team 👋
#DrugDiscovery #MultiOmics #Genomics #DrugDevelopment #FOG2026 #FrontLineGenomics

Day 1 at #FOG2026 is here 🚀 

You can find us at Booth #77 - come say hello to the team and try our iconic Mystra D&D Quest 🧙 - an interactive challenge that gives you a hands-on experience with our drug target discovery and development platform! 

🎤 Today | 12:00 - 12:30 | Multi-Omics stage
Join Dirk Paul, Head of Development, for "The Genome and Beyond: Advancing Drug Discovery and Development"
What to expect:
💡 Insights into Genomics' genotype-phenotype platform & analytical pipelines
🧬  A deep dive into how multi-omics integration drives target identification & data-driven patient stratification
🌍  Real-world case case studies showcasing risk prediction and pharmacomimetic approaches in action

See you on the floor 👋 

#drugdiscovery #MultiOmics #Genomics #DrugDevelopment Front Line Genomics

I'll be heading to JPM next week. If you’ll be there too, drop me a message, it’d be great to connect in person.

🎉 We're starting the year in San Francisco! Our team will be arriving later this week for the J.P. Morgan Healthcare Conference.

We are looking forward to a busy few days connecting with colleagues from the Department for Business and Trade, and senior leaders across pharma and biotech.

From Saturday, January 10th, our CEO and Co-Founder, Professor Sir Peter Donnelly, President David Thornton, VP of Client Service David Walker, and Director of Communications Zuzanna Grzeskiewicz will be on the ground in San Francisco, ready to connect.

If you're going to be in San Francisco next week and would like to meet with our team, click here: https://lnkd.in/eT9qFMyy

See you soon! 🚀 

#JPM2026 #JPMWeek #techbio #genomics #JPM #pharma #biotech #healthcare #SanFran

I help scaling agencies grow profitably through improving their internal operations.

After 18 years inside award-winning marketing and comms agencies, I know how easily margins, people, and creativity get squeezed when growth outpaces operations.

That’s why I now work with ambitious agency leaders to bring clarity to the way they forecast, price, deliver, and resource projects. So that growth feels predictable, teams stay motivated, and profit isn’t left to chance.

Depending on your agency and priorities, I typically offer:

🟣 Half-day workshop – uncover quick wins and hidden inefficiencies
🟣 Short consultancy – diagnose what’s working, what’s not, and prioritise fixes
🟣 Implementation support – embed new ways of working so improvements stick
🟣 Fractional ops leadership – guide ongoing clarity and scalable growth 

Whatever the format, my goal is the same: sustainable, profitable growth built on solid foundations.

Always happy to connect with other agency leaders navigating growth. Virtual coffee welcome!

taplio

The Battle

David Walker

Kate Bridge

Followers

Posts

Engagements

Likes

Performance ScoreDavid Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

David Walker

Kate Bridge

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}David Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreDavid Walker's LinkedIn Performance